Continuous subcutaneous infusion therapy with the apomorphine pump;Kontinuierliche Therapie mit der Apomorphinpumpe

Aktuelle Neurologie, Supplement

Volumn 38, Issue SUPPL. 1, 2011, Pages

  Ceballos Baumann, Andres ^a  

^a Zentrum für Parkinson Syndrome und Bewegungsstörungen   (Germany)

Author keywords

apomorphine; dopamine agonists; levodopa, L dopa; medication pumps; Parkinson disease

Indexed keywords

APOMORPHINE; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; GASTROSTOMY; HUMAN; MENTAL DISEASE; PARKINSON DISEASE; SEDATION; SKIN NODULE; SURGICAL TECHNIQUE;

EID: 79951983775     PISSN: 14372754     EISSN: 16117697     Source Type: Journal    
DOI: 10.1055/s-0030-1265977     Document Type: Article

References (43)

1. Struppler A, Uexkuell T v. Untersuchungen ueber die Wirkungsweise von Apomorphine auf den Parkinsontremor. Z Klin Med 1953 152 46-57
2. Cotzias G C., Papavasiliou P S., Fehling C et al. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970 282 31-33
3. Corsini G U., Del Zompo M, Gessa G L. et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine re (Pubitemid 9163649)
4. Stibe C M., Lees A J., Kempster P A. et al. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988 1 403-406 (Pubitemid 18047004)
5. Luginger E, Wenning G K., Bosch S et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000 15 873-878
6. Manson A J., Hanagasi H, Turner K et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001 124 331-340 (Pubitemid 32142405)
7. Dewey Jr R B., Hutton J T., LeWitt P A. et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001 58 1385-1392 (Pubitemid 32845989)
8. Manson A J., Turner K, Lees A J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002 17 1235-1241 (Pubitemid 36041337)
9. Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov Disord 2004 20 151-157 (Pubitemid 40361117)
10. Tyne H L., Parsons J, Sinnott A et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol 2004 251 1370-1374
11. Hughes A J., Lees A J., Stern G M. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991 41 1723-1725
12. Factor S A., Brown D L., Molho E S. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 2000 15 167-169 (Pubitemid 30038007)
13. Reuter I, Ellis C M., Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999 100 163-167 (Pubitemid 29376827)
14. Tison F, Wiart L, Guatterie M et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996 11 729-732 (Pubitemid 26381947)
15. Kempster P A., Lees A J., Crichton P et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989 4 47-52 (Pubitemid 19037947)
16. Bailbe M, Bataille B, Paquereau J et al. Improvement in swallowing difficulties treated by subcutaneous apomorphine infusion after deep brain stimulation in Parkinson's disease. Rev Neurol 2004 160 352-353 (Pubitemid 38391579)
17. Christmas T J., Kempster P A., Chapple C R. et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988 2 1451-1453 (Pubitemid 19016651)
18. Edwards L L., Quigley E M., Harned R K. et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993 33 490-493 (Pubitemid 23143032)
19. O'Sullivan J D. Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002 72 681 (Pubitemid 34462838)
20. O'Sullivan J D., Hughes A J. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998 13 536-539 (Pubitemid 28221510)
21. Di Rosa A E., Epifanio A, Antonini A et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci 2003 24 174-175 (Pubitemid 37304299)
22. Garcia Ruiz P J. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord 2006 21 727-728 (Pubitemid 43792764)
23. Eggert K et al. Parkinson-Syndrome - Diagnostik und Therapie. Leitlinien für Diagnostik und Therapie in der Neurologie. 4. überarbeitete Auflage. Stuttgart Thieme Verlag 2008
24. Chaudhuri K R., Critchley P, Abbott R J. et al. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet 1988 2 1260
25. Pollak P, Champay A S., Hommel M et al. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989 52 544
26. Kreczy-Kleedorfer B, Wagner M, Bosch S et al. Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease. Nervenarzt 1993 64 221-225 (Pubitemid 23194866)
27. Stocchi F, Bramante L, Monge A et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 1993 60 653-655
28. Hughes A J., Bishop S, Kleedorfer B et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993 8 165-170 (Pubitemid 23131637)
29. Gancher S T., Nutt J G., Woodward W R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995 10 37-43
30. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow up. J Neurol Neurosurg Psychiatry 1998 65 709-716 (Pubitemid 28486650)
31. Kanovsky P, Kubova D, Bares M et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002 17 188-191 (Pubitemid 36041277)
32. Morgante L, Basile G, Epifanio A et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl 2004 9 291-296 (Pubitemid 38822878)
33. De Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow-up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006 77 450-453
34. Garcia Ruiz P J., Sesar Ignacio A, Ares Pensado B et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008 23 1130-1136
35. Pollak P, Champay A S., Gaio J M. et al. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol 1990 146 116-122 (Pubitemid 20073637)
36. Colzi A, Turner K, Lees A J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998 64 573-576 (Pubitemid 28204140)
37. Ahmad N, Keith-Ferris J, Gooden E et al. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006 6 571-576 (Pubitemid 44660947)
38. Schoffer K L., Henderson R D., O'Maley K et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007 22 1543-1549 (Pubitemid 47477913)
39. Rabinak C A., Nirenberg M J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010 67 58-63
40. van Laar T, Postma A G., Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord 2010 16 71-72
41. Pinter M M., Helscher R J., Mundsperger N et al. Transient increase of pancreatic enzymes evoked by apomorphine in Parkinson's disease. J Neural Transm 1998 105 1237-1244 (Pubitemid 29017404)
42. Todd A, James C A. Apomorphine nodules in Parkinson's disease: best practice considerations. Br J Community Nurs 2008 13 457-463
43. Poltawski L, Edwards H, Todd A et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009 24 115-118